In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 301 to 350 of 423

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]	Technology appraisal guidance	28 May 2025
Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]	Technology appraisal guidance	TBC
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381	Technology appraisal guidance	16 April 2025
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]	Technology appraisal guidance	TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]	Technology appraisal guidance	TBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]	Technology appraisal guidance	TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
PillCam COLON 2 for investigation of the colon through direct visualisation	Diagnostics guidance	17 July 2025
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]	Technology appraisal guidance	TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]	Technology appraisal guidance	TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353	Technology appraisal guidance	TBC
Pneumonia: diagnosis and management (update)	NICE guideline	TBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]	Technology appraisal guidance	TBC
Pralsetinib for thyroid cancer [ID4018]	Technology appraisal guidance	TBC
Pulsed field ablation for atrial fibrillation	Interventional procedures guidance	9 July 2025
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]	Technology appraisal guidance	15 November 2017
Rehabilitation for chronic neurological disorders including acquired brain injury	NICE guideline	16 July 2025
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]	Technology appraisal guidance	TBC
Renal cell carcinoma Pathways Pilot [ID6186]	Technology appraisal guidance	TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]	Technology appraisal guidance	TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007	Technology appraisal guidance	TBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)	Technology appraisal guidance	TBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]	Technology appraisal guidance	18 June 2025
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]	Technology appraisal guidance	TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]	Technology appraisal guidance	TBC
Robot-assisted surgery for orthopaedic procedures: early value assessment	Health technology evaluation	31 March 2025
Robot-assisted surgery for soft-tissue procedures: early value assessment	Health technology evaluation	TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]	Technology appraisal guidance	TBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]	Technology appraisal guidance	TBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]	Technology appraisal guidance	TBC
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]	Technology appraisal guidance	29 January 2025
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]	Technology appraisal guidance	TBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]	Technology appraisal guidance	TBC
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention	Interventional procedures guidance	TBC
School-based interventions: physical and mental health and wellbeing promotion	Quality standard	TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284	Technology appraisal guidance	TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]	Technology appraisal guidance	TBC
Seladelpar for previously treated primary biliary cholangitis ID6429	Technology appraisal guidance	TBC
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]	Technology appraisal guidance	30 October 2024
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]	Technology appraisal guidance	TBC
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441	Technology appraisal guidance	TBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346	Technology appraisal guidance	TBC
Sipavibart for preventing COVID 19 [ID6282]	Technology appraisal guidance	TBC

Results per page

10
25
50
All